Answers are grounded in this paper and cite their sources.
Evaluates reporting and methodological quality of psoriasis guidelines, indicating the need for improved transparency.
Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 2–3% of the global population and is associated with substantial physical, psychological, and economic burden (1). Over the past decade, the therapeutic landscape for psoriasis has expanded considerably with the introduction of biologic agents targeting tumor necrosis factor α (TNF- α), interleukin 17 and 23 (IL-17, IL-23), prompting frequent revisions of clinical practice guidelines worldwide (2). Clinical practice guidelines (CPGs) are systematically developed statements intended to assist clinicians and patients in making evidence-based decisions. Their potential benefit, however, is contingent on both the rigour of their development and the transparency with which that development is reported. Variability in guideline quality has been repeatedly documented across medical specialties, and dermatology is no exception (3). The Global Guidelines in Dermatology Mapping Project (GUIDEMAP) (4) conducted the most comprehensive appraisal of psoriasis CPGs to date, evaluating 33 guidelines published between 2015 and March 2021 using the Appraisal of Guidelines for Research & Evaluation (AGREE) II instrument (5). This work identified substantial heterogeneity in methodological quality, with particular weaknesses in stakeholder involvement, rigour of development, and applicability. However, AGREE II assesses the process by which a guideline is developed and it does not evaluate whether that process is subsequently reported with sufficient completeness and transparency for readers to judge its trustworthiness. The Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement was developed specifically to address this complementary dimension, yet, to date, it has not been applied to any CPGs in the field of dermatology (6). In addition, a substantial number of new and updated psoriasis guidelines have been published since the GUIDEMAP search cut-off in March 2021. A guideline quality assessment that both extends the evidence base to 2026 and incorporates reporting quality alongside methodological rigour has not yet been undertaken.
No takes yet. Share an insight, caveat, or question.
Vitlov et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: